Role of the MPTP in conditioning the heart - Translatability and mechanism by Ong S. et al.
British Journal of Pharmacology 2015 vol.172 N8, pages 2074-2084
Role of the MPTP in conditioning the heart -
Translatability and mechanism
Ong S., Dongworth R., Cabrera-Fuentes H., Hausenloy D.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2014 The Authors. British Journal of Pharmacology published by John Wiley Sons Ltd on behalf
of  The  British  Pharmacological  Society.  Mitochondria  have  long  been  known  to  be  the
gatekeepers of cell fate. This is particularly so in the response to acute ischaemia-reperfusion
injury (IRI). Following an acute episode of sustained myocardial ischaemia, the opening of the
mitochondrial  permeability  transition  pore  (MPTP)  in  the  first  few  minutes  of  reperfusion,
mediates  cell  death.  Preventing  MPTP  opening  at  the  onset  of  reperfusion  using  either
pharmacological inhibitors [such as cyclosporin A (CsA) ] or genetic ablation has been reported
to  reduce  myocardial  infarct  (MI)  size  in  animal  models  of  acute  IRI.  Interestingly,  the
endogenous  cardioprotective  intervention  of  ischaemic  conditioning,  in  which  the  heart  is
protected against MI by applying cycles of brief ischaemia and reperfusion to either the heart
itself  or a remote organ or tissue, appears to be mediated through the inhibition of MPTP
opening  at  reperfusion.  Small  proof-of-concept  clinical  studies  have  demonstrated  the
translatability of this therapeutic approach to target MPTP opening using CsA in clinical settings
of acute myocardial IRI. However, given that CsA is a not a specific MPTP inhibitor, more novel
and specific inhibitors of the MPTP need to be discovered - the molecular identification of the
MPTP should facilitate this.  In this  paper,  we review the role of  the MPTP as a target for
cardioprotection,  the  potential  mechanisms  underlying  MPTP  inhibition  in  the  setting  of
ischaemic conditioning, and the translatability of MPTP inhibition as a therapeutic approach in
the clinical setting.
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